Gilead Sciences, Inc. (GILD) Stake Increased by Capital Bank & Trust Co

Capital Bank & Trust Co increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 116.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,197,728 shares of the biopharmaceutical company’s stock after purchasing an additional 643,218 shares during the quarter. Gilead Sciences accounts for about 1.2% of Capital Bank & Trust Co’s investment portfolio, making the stock its 23rd largest holding. Capital Bank & Trust Co’s holdings in Gilead Sciences were worth $97,040,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in GILD. Wheatland Advisors Inc. bought a new position in Gilead Sciences during the second quarter worth $2,150,000. Wetherby Asset Management Inc. lifted its stake in Gilead Sciences by 14.8% during the second quarter. Wetherby Asset Management Inc. now owns 41,256 shares of the biopharmaceutical company’s stock worth $2,920,000 after purchasing an additional 5,318 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Gilead Sciences by 6.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 4,706,832 shares of the biopharmaceutical company’s stock worth $333,150,000 after purchasing an additional 302,787 shares during the last quarter. Walter & Keenan Financial Consulting Co. MI ADV bought a new position in Gilead Sciences during the second quarter worth $269,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the last quarter. Hedge funds and other institutional investors own 75.84% of the company’s stock.

GILD has been the topic of several research analyst reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a research note on Friday, October 13th. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. BMO Capital Markets reduced their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Maxim Group set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $85.58.

In related news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the transaction, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 578,333 shares of company stock worth $44,100,508. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $82.76 on Thursday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market cap of $108,080.00, a PE ratio of 9.42, a P/E/G ratio of -1.73 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the previous year, the business earned $2.70 earnings per share. The company’s revenue was down 18.7% on a year-over-year basis. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s payout ratio is currently 23.66%.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2018/02/08/gilead-sciences-inc-gild-stake-increased-by-capital-bank-trust-co.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply